Prostate apoptosis response-4 is expressed in normal cholangiocytes, is down-regulated in human cholangiocarcinoma, and promotes apoptosis of neoplastic cholangiocytes when induced pharmacologically

American Journal of Pathology

Volumn 177, Issue 4, 2010, Pages 1779-1790

  Franchitto, Antonio ^a   Torrice, Alessia ^a   Semeraro, Rossella ^a   Napoli, Cristina ^a   Nuzzo, Gennaro ^b   Giuliante, Felice ^b   Alpini, Gianfranco ^c   Carpino, Guido ^d   Berloco, Pasquale Bartolomeo ^a   Izzo, Luciano ^a   Bolognese, Antonio ^a   Onori, Paolo ^e   Renzi, Anastasia ^a   Cantafora, Alfredo ^a   Gaudio, Eugenio ^a   Alvaro, Domenico ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c TEXAS A M COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF ROME FORO ITALICO   (Italy)

^e UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLINE; PROSTATE APOPTOSIS RESPONSE 4 PROTEIN; PROTEIN; PROTEIN BAX; PROTEIN BCL 2; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL CELL; APOPTOSIS; ARTICLE; BILE DUCT CARCINOMA; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; RAT;

EID: 77957353064     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2010.091171     Document Type: Article

References (41)

1. Blechacz B, Gores GJ: Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology 2008, 48(1):308-321
2. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD: Cholangiocarcinoma. Lancet 2005, 366(9493):1303-1314
3. Patel T: Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2002, 2:10
4. Fava G, Marzioni M, Benedetti A, Glaser S, DeMorrow S, Francis H, Alpini G: Molecular pathology of biliary tract cancers. Cancer Lett 2007, 250(2):155-167 (Pubitemid 46529440)
5. Alvaro D, Mancino MG: New insights on the molecular and cell biology of human cholangiopathies. Mol Aspects Med 2008, 29(1-2):50-57
6. Alvaro D, Crocetti E, Ferretti S, Bragazzi MC, Capocaccia R; the AISF "Cholangiocarcinoma" Committee. Descriptive epidemiology of cholangiocarcinoma in Italy. Dig Liver Dis 2009, Dec 18. [Epub ahead of print]
7. Sells SF, Wood DP, Joshi-Barve SS, Muthukumar S, Jacob RJ, Crist SA, Humphreys S, Rangnekar VM: Commonality of the gene programs induced by effectors of apoptosis in androgen-dependent and -independent prostate cells. Cell Growth Differ 1994, 5:457-466 (Pubitemid 24251397)
8. Goswami A, Qiu S, Dexheimer TS, Ranganathan P, Burikhanov R, Pommier Y, Rangnekar VM: Par-4 binds to topoisomerase 1 and attenuates its DNA relaxation activity. Cancer Res 2008, 68:1-9
9. Lee TJ, Lee JT, Kim SH, Choi YH, Song KS, Park JW, Kwon TK: Overexpression of Par-4 enhances thapsigargin-induced apoptosis via down-regulation of XIAP and inactivation of Akt in human renal cancer cells. J Cell Biochem 2008, 103(2):358-368
10. Diaz-Meco MT, Abu-Baker S: The Par-4/PTEN connection in tumor suppression. Cell Cycle 2009, 8(16):2518-2522
11. Fernandez-Marcos PJ, Abu-Baker S, Joshi J, Galvez A, Castilla EA, Cañamero M, Collado M, Saez C, Moreno-Bueno G, Palacios J, Leitges M, Serrano M, Moscat J, Diaz-Meco MT: Simultaneous inactivation of Par-4 and PTEN in vivo leads to synergistic NF-kappaB activation and invasive prostate carcinoma. Proc Natl Acad Sci USA 2009, 106(31):12962-12967
12. Kline CL, Shanmugavelandy SS, Kester M, Irby RB: Delivery of PAR-4 plasmid in vivo via nanoliposomes sensitizes colon tumor cells subcutaneously implanted into nude mice to 5-FU. Cancer Biol Ther 2009, 22:1831-1837
13. Burikhanov R, Zhao Y, Goswami A, Qiu S, Schwarze SR, Rangnekar VM: The tumor suppressor Par-4 activates an extrinsic pathway for apoptosis. Cell 2009, 138(2):377-388
14. Moscat J, Diaz-Meco MT, Wooten MW: Of the atypical PKCs, Par-4 and p62: recent understandings of the biology and pathology of a PB1-dominated complex. Cell Death Differ 2009, 16(11):1426-1437
15. Moreno-Bueno G, Fernandez-Marcos PJ, Collado M, Tendero MJ, Rodriguez- Pinilla SM, Garcia-Cao I, Hardisson D, Diaz-Meco MT, Moscat J, Serrano M, Palacios J: Inactivation of the candidate tumor suppressor par-4 in endometrial cancer. Cancer Res 2007, 67:1927-1934 (Pubitemid 46424208)
16. García-Cao I, Duran A, Collado M, Carrascosa MJ, Martín-Caballero J, Flores JM, Diaz-Meco MT, Moscat J, Serrano M: Tumour-suppression activity of the proapoptotic regulator Par4. EMBO Rep 2005, 6:577-583 (Pubitemid 40973968)
17. Barradas M, Monjas A, Diaz-Meco MT, Serrano M, Moscat J: The downregulation of the pro-apoptotic protein Par-4 is critical for Ras-induced survival and tumor progression. EMBO J 1999, 18(22):6362-6369
18. Zhao Y, Burikhanov R, Qiu S, Lele SM, Jennings CD, Bondada S, Spear B, Rangnekar VM: Cancer resistance in transgenic mice expressing the SAC module of Par-4. Cancer Res 2007, 67:9276-9285 (Pubitemid 47535916)
19. Srinivasan S, Ranga RS, Burikhanov R, Han SS, Chendil D: Par-4- dependent apoptosis by the dietary compound withaferin A in prostate cancer cells. Cancer Res 2007, 67(1):246-253 (Pubitemid 46142781)
20. Azmi AS, Ahmad A, Banerjee S, Rangnekar VM, Mohammad RM, Sarkar FH: Chemoprevention of pancreatic cancer: characterization of Par-4 and its modulation by 3,3′ diindolylmethane (DIM). Pharm Res 2008, 25(9):2117-2124
21. Azmi AS, Wang Z, Burikhanov R, Rangnekar VM, Wang G, Chen J, Wang S, Sarkar FH, Mohammad RM: Critical role of prostate apoptosis response-4 in determining the sensitivity of pancreatic cancer cells to small-molecule inhibitor-induced apoptosis. Mol Cancer Ther 2008, 7(9):2884-2893
22. Mennone A, Alvaro D, Cho W, Boyer JL: Isolation of small polarized bile duct units. Proc Natl Acad Sci USA 1995, 92(14):6527-6531
23. Alvaro D, Barbaro B, Franchitto A, Onori P, Glaser SS, Alpini G, Francis H, Marucci L, Sterpetti P, Ginanni-Corradini S, Onetti Muda A, Dostal DE, De Santis A, Attili AF, Benedetti A, Gaudio E: Estrogens and insulin-like growth factor 1 modulate neoplastic cell growth in human cholangiocarcinoma. Am J Pathol 2006, 169(3):877-888
24. Mancino A, Mancino MG, Glaser SS, Alpini G, Bolognese A, Izzo L, Francis H, Onori P, Franchitto A, Ginanni-Corradini S, Gaudio E, Alvaro D: Estrogens stimulate the proliferation of human cholangiocarcinoma by inducing the expression and secretion of vascular endothelial growth factor. Dig Liver Dis 2009, 41(2):156-163
25. Schroeder A, Mueller O, Stocker S, Salowsky R, Leiber M, Gassmann M, Lightfoot S, Menzel W, Granzow M, Ragg T: The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC Mol Biol 2006, 7:3
26. Cantafora A, Blotta I, Rivabene R, Pisciotta L, Bertolini S: Evaluation of RNA messengers involved in lipid trafficking of human intestinal cells by reverse-transcription polymerase chain reaction with competimer technology and microchip electrophoresis. S Electrophoresis 2003, 24:3748-3754
27. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F: Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002, 3(7):RESEARCH0034
28. Onori P, Alvaro D, Floreani AR, Mancino MG, Franchitto A, Guido M, Carpino G, De Santis A, Angelico M, Attili AF, Gaudio E: Activation of the IGF1 system characterizes cholangiocyte survival during progression of primary biliary cirrhosis. J Histochem Cytochem 2007, 55(4):327-334 (Pubitemid 46481940)
29. Lee TJ, Jang JH, Noh HJ, Park EJ, Choi KS, Kwon TK: Overexpression of Par-4 sensitizes TRAIL-induced apoptosis via inactivation of NF-kappaB and Akt signaling pathways in renal cancer cells. J Cell Biochem 2010, 109(5):885-895
30. Lin HI, Lee YJ, Chen BF, Tsai MC, Lu JL, Chou CJ, Jow GM: Involvement of Bcl-2 family, cytochrome c and caspase 3 in induction of apoptosis by beauvericin in human non-small cell lung cancer cells. Cancer Lett 2005, 230(2):248-259 (Pubitemid 41612468)
31. Mellier G, Huang S, Shenoy K, Pervaiz S: TRAILing death in cancer. Mol Aspects Med 2010, 31(1):93-112
32. Chen Y, Xu J, Jhala N, Pawar P, Zhu ZB, Ma L, Byon CH, McDonald JM: Fas-mediated apoptosis in cholangiocarcinoma cells is enhanced by 3,3′-diindolylmethane through inhibition of AKT signaling and FLICE-like inhibitory protein. Am J Pathol 2006, 169(5):1833-1842 (Pubitemid 351182012)
33. Zhao Y, Rangnekar VM: Apoptosis and tumor resistance conferred by Par-4. Cancer Biol Ther 2008, 7(12):1867-1874
34. Page G, Kogel D, Rangnekar V, Scheidtmann KH: Interaction partners of Dlk/ZIP kinase: co-expression of Dlk/ZIP kinase and Par-4 results in cytoplasmic retention and apoptosis. Oncogene 1999, 18:7265-7273 (Pubitemid 30032105)
35. Díaz-Meco MT, Municio MM, Frutos S, Sanchez P, Lozano J, Sanz L, Moscat J: The product of par-4, a gene induced during apoptosis, interacts selectively with the atypical isoforms of protein kinase C. Cell 1996, 86:777-786 (Pubitemid 26303446)
36. Diaz-Meco MT, Lallena MJ, Monjas A, Frutos S, Moscat J: Inactivation of the inhibitory kappaB protein kinase/nuclear factor kappaB pathway by Par-4 expression potentiates tumor necrosis factor alpha-induced apoptosis. J Biol Chem 1999, 274(1):9606-9612 (Pubitemid 129519402)
37. Chung JY, Hong SM, Choi BY, Cho H, Yu E, Hewitt SM: The expression of phospho-AKT, phospho-mTOR, and PTEN in extrahepatic cholangiocarcinoma. Clin Cancer Res 2009, 15(2):660-667
38. Xu X, Kobayashi S, Qiao W, LiC J: Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice. Clin Invest 2006, 116(7):1843-1852
39. Kaul MK, Kumar A, Ahuja A, Mir BA, Suri KA, Qazi GN: Production dynamics of Withaferin A in Withania somnifera (L.) Dunal complex. Nat Prod Res 2009, 23(14):1304-1311
40. Yu Y, Hamza A, Zhang T, Gu M, Zou P, Newman B, Li Y, Gunatilaka AA, Zhan CG, Sun D: Withaferin A targets heat shock protein 90 in pancreatic cancer cells. Biochem Pharmacol 2010, 79(4):542-551
41. Shaib YH, El-Serag HB, Davila JA, Morgan R, McGlynn KA: Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology 2005, 128(3):620-626